Oral propranolol and its impact on vital signs in hospitalized pediatric patients for the Management of Infantile Hemangiomas
Our findings complement current literature confirming that propranolol initiation is safe in pediatric patients. Propranolol initiation likely requires less laboratory and vital sign monitoring than currently performed for these patient populations.
Authors
- Katelyn J. Rypka (ORCID: https://orcid.org/0000-0002-5086-7679)
- Briana Paiewonsky (ORCID: https://orcid.org/0000-0002-9817-4871)
- Rebecca Freese (ORCID: https://orcid.org/0000-0001-9477-4231)
- Cynthia L. Nicholson (ORCID: https://orcid.org/0000-0001-6144-093X)
- Gretchen Bellefeuille
- Sheilagh Maguiness (ORCID: https://orcid.org/0000-0002-0033-8285)
- Zachary Wendland (ORCID: https://orcid.org/0000-0002-3833-4781)
Institutions
- University of Minnesota (US)
- Minneapolis VA Medical Center (US)
- Florida Atlantic University (US)
Publication Details
- Journal
- Pediatric Dermatology
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1111/pde.15740
- Primary Topic
- Vascular Malformations and Hemangiomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences